Scarica l'app Stockscreener
4.18
2.34%
-0.10
Dopo l'orario di chiusura:
4.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Titan Pharmaceuticals Inc De Borsa (TTNP) Ultime notizie
Automated trading signals detected on Titan Pharmaceuticals Inc.Market Risk Analysis & Pattern Based Trade Signal System - newser.com
$17.25M IPO Complete: Biotech Curanex Pharmaceuticals Secures Full Over-Allotment Exercise at $4/Share - Stock Titan
$6M Funded Breakthrough: Lobe Sciences Unveils Revolutionary Psilocin Treatment for Chronic Cluster Headaches - Stock Titan
$251 Million Capital Raise: Dianthus Therapeutics Secures Major Funding for Autoimmune Drug Development - Stock Titan
Global Pharma Leader and Sinclair Pharma Co-Founder Joins Lobe Sciences' Board of Directors - Stock Titan
Targeting 10,000 Patients by 2026: HOPE Therapeutics Acquires Dura Medical in Florida Mental Health Expansion - Stock Titan
Major Pharma Merger Advances: Semnur Pharmaceuticals-Denali Capital Deal Gets Shareholder Green Light - Stock Titan
Biotech Acurx Pharmaceuticals Secures Future on Nasdaq by Meeting Critical $1 Bid, $2.5M Equity Rules - Stock Titan
Is Titan Pharmaceuticals Inc. trending in predictive chart models2025 Biggest Moves & Verified Entry Point Signals - Newser
Using Python tools to backtest Titan Pharmaceuticals Inc. strategiesJuly 2025 Short Interest & Weekly Top Performers Watchlists - Newser
Neuroscience Biotech Xenon Pharmaceuticals Awards $2.1M in Stock Options to Expand Drug Development Team - Stock Titan
$30M Stock Offering: Cognition Therapeutics Advances Phase 3 Programs for Neurodegenerative Drug - Stock Titan
$15 Million IPO: Inflammatory Disease Biotech Curanex Launches on Nasdaq with Botanical Drug Focus - Stock Titan
Titan Pharmaceuticals Stock Surges 23% After Hours on Stockholder Approval of Three-Way Merger - Benzinga
$15 Million IPO: Botanical Drug Developer Curanex Lists on Nasdaq to Advance Ulcerative Colitis Treatment - Stock Titan
$80 Million Cash Distribution: ESSA Pharma Corrects Due Bill Trading Period Ahead of XenoTherapeutics Deal - Stock Titan
Sector ETF performance correlation with Titan Pharmaceuticals Inc.2025 Price Targets & AI Optimized Trading Strategy Guides - Newser
Will a bounce in CEMEX S.A.B. de C.V. Depositary Receipt offer an exitJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - Newser
13M Patient Market: NRx Pharmaceuticals Secures Major FDA Fast Track Win for Revolutionary Depression Drug - Stock Titan
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 304.7% in July - Defense World
Elite Pharmaceuticals Revenue More Than Doubles as New ADHD Drug Launch Drives Record Growth - Stock Titan
How Titan Pharmaceuticals Inc. stock performs during market volatilityMarket Growth Summary & Expert Curated Trade Ideas - Newser
ESSA Pharma Shareholders to Get $1.69 Per Share as Company Prepares for XenoTherapeutics Deal - Stock Titan
Sonoma's First Major Consumer Product Hits Walmart Shelves: New Tech-Based Diaper Rash Treatment - Stock Titan
Ketamir-2 outperforms ketamine, plans Phase 2a FDA submission in Q4 2025 - Stock Titan
X4 Pharmaceuticals Overhauls Leadership: $60M Deal Brings CTI BioPharma's $1.7B Exit Team Onboard - Stock Titan
CVKD Files 8-K; Exhibit 99.1 Contains Q2 2025 Financials - Stock Titan
FDA Fast Track Breakthrough: NRX-100 Shows 63% Success Rate in Suicidal Depression Treatment - Stock Titan
Will earnings trigger a reversal in Titan Pharmaceuticals Inc.Daily Swing Candidate Analysis with Chart Patterns - Newser
Best Pharmaceutical Stocks to Buy in 2025 - The Motley Fool
Elite Pharmaceuticals Earnings Call: Key Corporate Updates and Q1 2026 Results Coming August 15 - Stock Titan
NRx Secures Florida Approval to Acquire Veterans Mental Health Provider Dura Medical - Stock Titan
Kiora's Q2 Earnings Reveal Dual Phase 2 Trials Progress and $110M Asia Partnership Opportunity - Stock Titan
PLBY regains Nasdaq compliance with new independent director appointment | PCSA SEC FilingForm 8-K - Stock Titan
Biotech Pioneer Processa Pharmaceuticals Embraces Crypto: Strategic Investment Meets Blockchain Innovation - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
RIGL files S-8 to register 825,000 shares for employee equity plans | RIGL SEC FilingForm S-8 - Stock Titan
Verrica Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Dermatology Pipeline - Stock Titan
TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc.TTNP - FinancialContent
Cumberland Pharmaceuticals Hits 23% Revenue Growth as DMD Drug Shows Major Heart Benefits - Stock Titan
Nuvectis Reports Clinical Trial Success: NXP900 Cancer Drug Advances as Cash Position Strengthens to $39M - Stock Titan
Biotech Terns Pharmaceuticals Appoints Chief People Officer, Awards Massive 500,000 Share Option Package - Stock Titan
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
Pharmaceutical Pioneer Artelo Makes History: Raises $9.5M to Build First-Ever Solana Treasury Strategy - Stock Titan
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
SHEN files 8-K, releases Q2 2025 earnings press release | ADIL SEC FilingForm 424B5 - Stock Titan
Acurx Pharmaceuticals Plans Major 1:20 Reverse SplitKey Details for Nasdaq Compliance - Stock Titan
Lexicon Pharmaceuticals Meets $1 Minimum Share Price, Secures Critical Nasdaq Listing Status - Stock Titan
Apellis Scores Major FDA Approval for EMPAVELI, Secures $300M Deal and Reports Strong Q2 Earnings - Stock Titan
Cumberland Pharmaceuticals Sets Q2 Earnings Date: FDA-Approved Drug Portfolio Update Coming August 5 - Stock Titan
NRx Pharmaceuticals Teams with Yale Expert to Reveal Latest CNS Treatment Innovations at BTIG Conference - Stock Titan
Windtree Eliminates 99% of Preferred C Shares as BNB Crypto Strategy Sees 17% Gain - Stock Titan
INM files 8-K on upcoming INM-901 Alzheimer’s data at AAIC 2025 | INM SEC FilingForm 8-K - Stock Titan
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
What are the latest earnings results for Titan Pharmaceuticals Inc.Achieve explosive financial results today - Jammu Links News
Phio Pharmaceuticals Advances Cancer Drug Production with Strategic US Manufacturing Partnership - Stock Titan
Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan
Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call - Stock Titan
Cancer Research Biotech Liminatus Makes Strategic Move into Blockchain Treasury Management - Stock Titan
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
Tonix Tackles 15-Year Fibromyalgia Treatment Void with Groundbreaking Patient Support Campaign - Stock Titan
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire
What analysts say about Titan Pharmaceuticals Inc. stockFree Smart Trading Workshop - jammulinksnews.com
0.25%
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):